FIERCELY
FOCUSED

on the development of novel
treatments for patients with
B-cell malignancies and
autoimmune diseases.

Learn
about us

Explore our
pipeline

investor
Information

Read our
publications

Latest News

TG Therapeutics Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated M...

TG received guidance from the FDA allowing submission of a single NDA for Marginal Zone Lymphoma (MZL) and Follicular Lymphoma indications Completion of rolling submission for the MZL/FL NDA expected in 1H20 NEW YORK , Jan. 16, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics , Inc. (NASDAQ: TGTX), a

Read More >

2 Gansevoort Street, 9th Floor
New York, NY 10014

Email Us (212) 554-4484